Aims: To spot the light on metastatic tumors to the breast which represent only 0.5-1.5% of breast malignancies to avoid misdiagnosis as primary breast tumors. Presentation of the Case: 45-year-old female was referred to the Oncology Department of Meet Ghmmr Oncology Center in November 2017 after total thyroidectomy followed by cervical lymph node dissection for medullary thyroid carcinoma (MTC) 1 year ago at Oncology Center Mansoura University. The panel recommended postoperative radiotherapy. One month after the end of radiotherapy, she complained of frequent headache attacks and abdominal pain. CT was done in February 2018 revealed metastasis to the brain, lung, liver and ovaries. After the fifth cycle of chemotherapy, a progressively enlarging left breast mass appeared, that proved to be metastatic MTC. Halim et al.; JCTI, 9(3): 1-6, 2019; Article no.JCTI.50829 2 Discussion: MTC is a neuroendocrine tumor of the thyroid gland. Breast is an unusual metastatic site for MTC. Consequently, breast masses should be evaluated with caution, especially in the presence of a known primary malignancy. Histopathologic examination is the key diagnostic tool. Conclusion: Metastasis to the breast should be considered in the differential diagnosis of a breast mass in a patient with a past history of MTC. Histopathologic examination and proper panel of immunohistochemical markers are fundamental for diagnosis to prevent unneeded surgery.
INTRODUCTION
Metastatic disease of the breast is usually secondary to malignancy in the contralateral breast. However, it is more prevalent in malignant lymphoma, malignant melanoma, and lung cancer [1] . However, the incidence of any metastasis to the breast is rare, comprising only 0.5-1.5% of breast malignancies [2] . The incidence of breast metastases may by underdiagnosed, with an autopsy series, the incidence was closer to 6% [3] . It has been reported that the rarity of metastases to the breast may be due to the replacement of the glandular tissue with connective or adipose tissues with corresponding reduction in blood flow, at the age when cancer development is most likely. On the contrary, primary breast carcinoma commonly metastasizes to the thyroid gland [4] . MTC is a neuroendocrine tumor that arises from parafollicular C cells. It is either of a sporadic fashion or inherited, which is related to germline mutations of the RET gene. Metastasis is commonly the first presentation, frequently within the neck lymph nodes, followed by the liver, lungs, and bones [5] .
We present a case of a 45-year-old female presenting with a lump in the breast, which was later diagnosed as a metastasis from MTC.
CASE PRESENTATION
This is a case of 45-year-old female was referred to the Oncology Department of Meet Ghmmr Oncology Center in November 2017 after total thyroidectomy followed by cervical lymph node dissection for MTC 1 year ago at Oncology Center Mansoura University. The pathological examination of the thyroid gland ( Fig. 1) After the fifth cycle, a progressively enlarging left breast mass appeared, from which needle biopsy was done. Sections showed monotonous rounded tumor cells, which were arranged in cords and in concentric manner around uninvolved mammary ducts. Carcinoma in situ either ductal or lobular were not detected (Fig. 2) . Considering the patient past history, metastasis from MTC was suspected. However, lobular carcinoma of the breast could not be excluded. Further IHC was done (Fig. 3) . The neoplastic cells were positive TTF-1, calcitonin, synaptophysin, chromogranin. On the other hand, it was negative for mammaglobin excluding mammary carcinoma. Consequently a diagnosis of metastatic MTC to the breast was concluded.
Unfortunately, progressive deterioration of the patient general condition happened and she died in October 2018.
DISCUSSION
MTC is a neuroendocrine tumor of the thyroid gland arises from the para follicular c cells which secrete calcitonin. It accounts for 5-8% of all thyroid cancers. MTC occurs in two settings; sporadic and hereditary pattern. Hereditary MTC represent about 20 -30% usually in the setting of multiple endocrine neoplasia type 2 (MEN 2) due to germline mutations of the RET proto oncogene [6] .
Metastasis to regional lymph nodes usually present at the time of diagnosis [7 metastases outside the neck may occur in the liver, lungs, bones and, less frequently, brain and skin.
Persistent hypercalcitonemia after thyroidectomy and lymph node dissection is highly related to occult distant metastases [6 A review of 20 cases of metastatic breast was described by Mandanas and colleges Imaging findings are similar to those of benign tumors [15] . It is the fundamental role of the pathologist to accurately diagnose metastatic tumors to the breast to avoid unneeded surgery. The retention of the normal histological structure of the mammary gland and lack of ductal or Both mammaglobin and GATA3 are specific markers for normal mammary tissue and primary breast carcinoma unlike the lack of [16] .
Concerning the medical treatment plan of our case, the cytotoxic drugs were not durable which is in accordance with literature [17] . Cytotoxic drugs based on decarbazine achieve acceptable toxicity profile and disease stabilization without long lasting marvelous responses [16] . Although the use of tyrosine kinase inhibitors is encouraged by treatment guidelines [18] , inavilability at Meet Ghmmr Oncology Center did not allow their use.
CONCLUSION
Metastasis to the breast from MTC is very rare. It should be considered in the differential diagnosis of a breast mass in a patient with history of MTC.
Normal mammary histology and absence of carcinoma in situ are important features to be noted. Proper panel of IHC markers can lead to a correct diagnosis and prevent unneeded surgery.
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